Ian Ingram

Ian Ingram

Authors >

Ian Ingram

Ian Ingram joined MedPage Today in 2018 as Deputy Managing Editor, and covers oncology for the site. Ian Ingram has been a medical editor for the past decade. Prior to joining MedPage Today, he was managing editor of Cancer Network, directing the website’s news coverage and video production. Ian has also worked as a fact-checker, was an assistant editor at Narrative Magazine, and a manuscript reader at the Paris Review. He holds a B.A. in journalism from Purchase College. Ian lives in Connecticut, enjoys tennis, and almost always bowls a perfect game.

Connect:

email image

Latest from Ian Ingram

FDA APPROVED upadacitinib (Rinvoq) over a computer rendering of inflamed intestines in a transparent body.

First JAK Inhibitor Approved for Crohn's Disease

Upadacitinib lands indication for moderately to severely active disease in adults

FDA ADCOMM obeticholic acid (Ocaliva) over a computer rendering of a liver with fibrosis.

NASH Drug Candidate Comes With 'Serious Risks,' Says FDA Staff

Agency reviewers signal little support for first potential nonalcoholic steatohepatitis drug

A photo of a male leprosy patient’s deformed hand.

Potential 'Game Changer' for Leprosy Prevention

Trial sees success with single dose of prophylactic rifapentine for household contacts

A computer rendering of mpox viruses.

CDC Alerts Over Potential Mpox Resurgence

"Outbreak is not over," agency says, as Chicago-area cluster prompts investigation

A photo of Nerf guns and foam bullets.

Foam Bullets Tied to Growing Number of Kids' Eye Injuries

Researchers at Parisian ED tally potential sight-threatening injuries over the past decade

A photo of a Subway restaurant beyond a McDonald's drive thru.

Food 'Swamps' Tied to Elevated Mortality From Obesity-Related Cancers

Study suggests diet is not necessarily a modifiable risk factor for all, editorialists say

FDA APPROVED RSV prefusion F protein vaccine (Arexvy) over a computer rendering of RSV viruses.

FDA Approves First-Ever RSV Vaccine

Respiratory syncytial virus vaccine indicated for adults 60 and up

A close up photo of a bag of intravenous fluid with an out of focus patient in the ICU in the background.

Botanical Product Reduces Sepsis Mortality in Chinese Trial

But path to FDA approval for Xuebijing infusion unlikely with these data alone, say editorialists

FDA EUA Pfizer-BioNTech COVID-19 Vaccine, Bivalent over a toddler getting vaccinated.

FDA Allows Extra Doses of Bivalent COVID Vax for Immunocompromised Tots

More doses of Pfizer's vaccine can be administered at the discretion of healthcare providers

FDA APPROVED Vowst over a microscope image of C. difficile bacteria.

FDA OKs First Poop-Based Oral Therapy

Vowst approved for preventing recurrent C. difficile infections after antibiotics

1

…